Vaccine Development

• Background
• Clinical Trials
• News and Publications

ID93/GLA-SE, designed by the Infectious Disease Research Institute (IDRI), is composed of an recombinant fusion-protein antigen plus IDRI’s proprietary adjuvant, GLA, which has been previously tested in humans, but has not been used in any other TB vaccine currently in clinical development. The vaccine candidate targets both active tuberculosis and latent TB. 

The vaccine candidate targets both active tuberculosis and latent TB, which lies dormant in one-third of the world’s population and reactivates when their immune systems are compromised.